The report “Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User – Global Forecast to 2027″, is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 Billion in 2022, at a CAGR of 14.2%. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.
Browse 97 market data Tables and 32 Figures spread through 142 Pages and in-depth TOC on “Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User – Global Forecast to 2027″
View detailed Table of Content here – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877
The Services segment accounted for the largest share of the Hemato oncology testing devices market, by product type, in 2021
On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits. The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the high and growing prevalence of leukemia and lymphoma.
The segment accounted for the largest share of the Hemato oncology testing devices market, by cancer type, in 2021
By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market. This can be attributed to factor such as the increasing prevalence and incidence of lymphoma is a major driving factor for this market.
PCR segment is anticipated to hold major share of the global Hemato oncology testing market in 2021
By technology, the global hemato oncology testing market is broadly segmented into PCR, IHC, NGS, cytogenetics, and other technologies. In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is the wide use of this technology owing to its ease of use and easy availability of assay kits.
North America to hold a significant share of the Hemato oncology testing market during the forecast period in 2021
The global hemato oncology testing market is segmented into North America, Europe, Asia Pacific, and ROW. North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests.
The major players operating in the Hemato oncology testing market Abbott Laboratories (US), F. Hoffman-La Roche (Switzerland), QIAGEN (Germany), Thermo Fisher Scientific (US), Illumina (US), Bio-Rad Laboratories (US), MolecularMD (Ireland), ArcherDX (US), ARUP Laboratories (US), Asuragen (US), Invivoscribe (US), Adaptive Biotechnologies (US), Amoy Diagnostics (China), ELITechGroup (France), Vela Diagnostics (Singapore), Gentronix (UK), BioIVT (US), SAGA Diagnostics (Sweden), Olink (Sweden) and Cancer Diagnostics (US).
Request Sample Pages:
Don’t miss out on business opportunities in Hemato Oncology Testing Market. Speak to our analyst and gain crucial industry insights that will help your business grow.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441